Table 1.

HPV prevalence in OPC by gender and corresponding M/F ratios by country, region, and the HPV detection method

PCRmRNA/ISH
MaleFemaleMaleFemale
Country or regionOPC (N)HPV prevalence (%)OPC (N)HPV prevalence (%)M/F ratio (95% CI)OPC (N)HPV prevalence (%)OPC (N)HPV prevalence (%)M/F ratio (95% CI)
Canada12560.03545.71.3 (0.9–1.9)8267.12962.11.1 (0.8–1.5)
United States1,32266.333245.21.5 (1.3–1.7)1,42161.530139.91.5 (1.3–1.8)
 North America1,44765.836745.21.5 (1.31.6)1,50361.833041.81.5 (1.31.7)
Australia37549.311439.51.3 (1.0–1.6)— (—)
The Netherlandsa69921.835014.91.5 (1.1–1.9)— (—)
Norway9956.63839.51.4 (0.9–2.2)— (—)
United Kingdom24260.37957.01.1 (0.9–1.3)39252.013644.11.2 (1.0–1.5)
Sweden42659.416157.81.0 (0.9–1.2)— (—)
Czech Republic14156.02965.60.9 (0.6–1.2)— (—)
France50840.613561.50.7 (0.6–0.9)— (—)
Germany55036.017454.00.7 (0.6–0.8)33020.010932.10.6 (0.4–0.9)
Italia8921.43030.00.8 (0.4–1.5)— (—)
 Europe2,75440.399641.21.0 (0.91.1)72237.424538.81.0 (0.91.2)
Korea— (—)13451.52138.11.1 (0.7–1.8)
Japan15933.33351.50.7 (0.4–1.0)— (—)
Taiwan34026.83271.90.4 (0.3–0.6)— (—)
 Asia49928.96561.50.5 (0.40.6)13451.52138.11.1 (0.71.8)
  • aHPV testing was restricted to p16-positive OPC. HPV prevalence cannot be compared with other countries, although the M/F ratio should be consistent.